Stefan Loren - Net Worth and Insider Trading
Stefan Loren Net Worth
The estimated net worth of Stefan Loren is at least $3,597 dollars as of 2024-05-16. Stefan Loren is the Director of Genvec Inc and owns about 500 shares of Genvec Inc (GNVC) stock worth over $3,597. Details can be seen in Stefan Loren's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Stefan Loren has not made any transactions after 2015-11-16 and currently still holds the listed stock(s).
Transaction Summary of Stefan Loren
Stefan Loren Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Stefan Loren owns 3 companies in total, including Cellectar Biosciences Inc (CLRB) , Genvec Inc (GNVC) , and Adhera Therapeutics Inc (ATRX) .
Click here to see the complete history of Stefan Loren’s form 4 insider trades.
Insider Ownership Summary of Stefan Loren
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CLRB | Cellectar Biosciences Inc | 2020-06-24 | director |
| GNVC | Genvec Inc | 2017-06-16 | director |
| ATRX | Adhera Therapeutics Inc | 2012-08-20 | director |
Stefan Loren Latest Holdings Summary
Stefan Loren currently owns a total of 1 stock. Stefan Loren owns 500 shares of Genvec Inc (GNVC) as of November 16, 2015, with a value of $3,597.
Latest Holdings of Stefan Loren
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GNVC | Genvec Inc | 2015-11-16 | 500 | 7.19 | 3,597 |
Holding Weightings of Stefan Loren
Stefan Loren Form 4 Trading Tracker
According to the SEC Form 4 filings, Stefan Loren has made a total of 0 transactions in Genvec Inc (GNVC) over the past 5 years. The most-recent trade in Genvec Inc is the acquisition of 400 shares on November 16, 2015, which cost Stefan Loren around $7,720.
Insider Trading History of Stefan Loren
- 1
Stefan Loren Trading Performance
GuruFocus tracks the stock performance after each of Stefan Loren's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stefan Loren is -17.39%. GuruFocus also compares Stefan Loren's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stefan Loren within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Stefan Loren's insider trading performs compared to the benchmark.
Performance of Stefan Loren
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 34.7 | | | | | |
| Relative Return to S&P 500(%) | 35.76 | | | | | |
Stefan Loren Ownership Network
Stefan Loren Owned Company Details
What does Cellectar Biosciences Inc do?
Who are the key executives at Cellectar Biosciences Inc?
Stefan Loren is the director of Cellectar Biosciences Inc. Other key executives at Cellectar Biosciences Inc include Senior Vice President & Medical Andrei Shustov , Chief Commercial Officer Darrell Shane Lea , and Chief Financial Officer Chad J Kolean .
Cellectar Biosciences Inc (CLRB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Cellectar Biosciences Inc (CLRB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cellectar Biosciences Inc (CLRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Cellectar Biosciences Inc (CLRB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cellectar Biosciences Inc Insider Transactions
Stefan Loren Mailing Address
Above is the net worth, insider trading, and ownership report for Stefan Loren. You might contact Stefan Loren via mailing address: 3226 Avenida De Sueno, Carlsbad Ca 92009.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
